Haemonetics Corp. (HAE) Tops Q4 EPS by 2c, Announces Buyback Plan and Posts FY12 Guidance

Haemonetics Corp. (NYSE: HAE) reported Q4 adjusted EPS of $0.85, $0.02 better than the analyst estimate of $0.83. Revenue for the quarter came in at $170 million versus the consensus estimate of $180.31 million.

Haemonetics Corp. sees FY2012 EPS of $3.50-$3.62, versus the consensus of $3.56. Haemonetics announced its fiscal 2012 annual guidance for organic revenue growth of 4-6%.

he Company announced that its Board of Directors has approved a $50 million share repurchase.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Verra Mobility (VRRM) Tops Q3 EPS by 10c ; Offers Guidance
• Mohawk Industries approves $500M share buyback, outlines capital plan
• Dominion Energy (D) Tops Q3 EPS by 9c, Beats on Revenue; Offers FY26 EPS Guidance